Recently, a new technique has been developed, where new genes are introduced into the body to help fight against cancer cells. Gene therapies are regarded as a potential revolution in the health sciences and pharmaceutical fields. The number of clinical trials investigating gene therapies is on an increase, despite the limited number of products that have successfully reached the market. In addition, benefits of gene therapy over conventional cancer therapies and increase in government support fuel the growth of the gene therapy market.
The gene therapy market is a widely expanding field in the pharmaceutical industry with new opportunities. This has piqued the interests of venture capitalists to explore this market and its commercial potential. Major factors that drive the growth of this market include high demands for DNA vaccines to treat genetic diseases, targeted drug delivery, and high incidence of genetic disorders. However, the stringent regulatory approval process for gene therapy and the high costs of gene therapy drugs are expected to hinder the growth of the market. On the contrary, increase in the pipeline developments for gene therapy market are expected to provide lucrative opportunity during the forecast period.
The global gene therapy market is segmented based on vector type, gene type, application, and geography. Based on vector type, it is categorized into viral vector and non-viral vector. Viral vector is further segmented into retroviruses, lentiviruses, adenoviruses, adeno associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. Non-viral vector is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others. Based on gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others. Based on application, the market is divided into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and other diseases. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key MARKET BENEFITS FOR STAKEHOLDERS
- This report offers a detailed quantitative analysis of the current market trends from 2018 to 2026 to identify the prevailing opportunities.
- The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
- In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.
- The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Vector Type
- Viral vector
- Retroviruses
- Lentiviruses
- Adenoviruses
- Adeno Associated Virus
- Herpes Simplex Virus
- Poxvirus
- Vaccinia Virus
- Others
- Non-viral vector
- Naked/Plasmid Vectors
- Gene Gun
- Electroporation
- Lipofection
- Others
By Gene Type
- Antigen
- Cytokine
- Tumor Suppressor
- Suicide
- Deficiency
- Growth factors
- Receptors
- Others
By Application
- Oncological Disorders
- Rare Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Infectious disease
- Other Diseases
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
KEY PLAYERS PROFILED
- Adaptimmune Therapeutics Plc.
- Anchiano Therapeutics Ltd.
- Achieve Life Sciences, Inc.
- Adverum Biotechnologies, Inc.
- Abeona Therapeutics Inc.
- Applied Genetic Technologies Corporation
- Arbutus Biopharma Corporation,
- Audentes Therapeutics, Inc.
- AveXis, Inc.
- Bluebird Bio, Inc.
- Celgene Corporation
- CRISPR Therapeutics AG
- Editas Medicine, Inc.
- Editas Medicine, Inc.
- GlaxoSmithKline Plc.
- Intellia Therapeutics, Inc.
- Merck & Co., Inc.
- Novartis AG
- REGENXBIO Inc.
- Spark Therapeutics, Inc.
- Sangamo Therapeutics, Inc.
- Uniqure N. V.
- Voyager Therapeutics, Inc
The other players of the gene therapy market include (companies not profiled in the report):
- Amgen
- Epeius Biotechnologies
- Sanofi
- Juno Therapeutics
- Advantagene
Table of Contents
Executive Summary
According to the report titled, 'Gene Therapy Market by Vector Type, Gene Type, and Application: Global Opportunity Analysis and Industry Forecast, 2019-2026', the gene therapy market size was $393.35 million in 2018, and is estimated to reach $6,205.85 million by 2026, registering a CAGR of 34.8% from 2019 to 2026.Gene therapies are promising therapies applicable to a broad range of diseases; their aim is to radically treat the causes of the diseases instead of only relieving the symptoms. They may be effective on a wide range of previously untreated diseases, such as hematological, ocular, neurodegenerative diseases, and several cancers. For example, adeno associated AAV2 vectors carrying the therapeutic gene (RPE65) intra-retinal injection resulted in improved vision for people with Leber’s Congenital Amaurosis. Gene therapies can be applied either in combination with cell products and through an ex vivo treatment mode (e.g. Strimvelis), or directly administered in vitro (e.g. Glybera). Several vectors present clinically relevant options, including adenovirus (AV), adeno-associated virus (AAV), and lentivirus.
The increase in funding for R&D activities pertaining to gene therapy and increase in awareness regarding gene therapy are the major factors that drive the gene therapy market growth. In addition, increase in government support, ethical acceptance of gene therapy for cancer treatment, and rise in prevalence of cancer can fuel the growth of the gene therapy market. However, high cost associated with the treatment and unwanted immune responses are expected to hamper the growth of the gene therapy market.
Among the vector type, non-viral vector is anticipated to be a lucrative in the global gene therapy market, due to the technological advancements such as physicochemical approaches that includes material such as lipid, naked DNA, chromosomes, plasmid, cationic polymers, and conjugate complexes of these vectors with positive results for these therapies during the preclinical and clinical trials for the treatment of various diseases.
Among the gene type, antigen dominates the overall market accounting for two-ninths of the global gene therapy market share in 2018. Among the applications, oncological disorders segment is the largest contributor towards the growth of the gene therapy market, owing to due to the availability of many gene therapy products that can be used to treat cancer and large patient population base. In addition, there are large number of gene therapies undergoing clinical trials for cancer and cardiovascular diseases.
In 2018, North America accounted for maximum contribution to the total revenue generated, and is anticipated to continue this gene therapy market trends during the forecast period. This is attributed to the high prevalence rate of cancer, presence of high disposable income, and high funding for R&D activities associated with gene therapy. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period owing to rise in incidence rate of cancer, increase in government initiative to improve healthcare infrastructure, and rise in healthcare expenditure.
Key Findings of the Gene Therapy Market:
Non-viral vectors segment is projected to grow at the highest rate with the CAGR of 34.6% during the analysis period.
Oncological disorders segment generated the highest revenue, and is expected to continue its dominance in future in the global gene therapy market.
Asia-Pacific is projected to grow at the fasted CAGR during the forecast period.
China is expected to grow highest in the Asia-Pacific region during the forecast period.
Tumor suppressor is the expected to grow fastest during the forecast period.
The report provides a comprehensive analysis of the key players operating in the global gene therapy market industry, namely Adaptimmune Therapeutics Plc., Anchiano Therapeutics Ltd., Achieve Life Sciences, Inc., Adverum Biotechnologies, Inc., Abeona Therapeutics Inc., Applied Genetic Technologies Corporation, Arbutus Biopharma Corporation, Audentes Therapeutics, Inc., AveXis, Inc., Bluebird Bio, Inc., Celgene Corporation, CRISPR Therapeutics AG, Editas Medicine, Inc., Editas Medicine, Inc., GlaxoSmithKline Plc., Intellia Therapeutics, Inc., Merck & Co., Inc., Novartis AG, REGENXBIO Inc., Spark Therapeutics, Inc., Sangamo Therapeutics, Inc., Uniqure N. V., Voyager Therapeutics, Inc.
Other prominent players in the value chain (companies not profiled in the report) includes Amgen, Epeius Biotechnologies, Sanofi, Juno Therapeutics, and Advantagene.
Companies Mentioned
- Adaptimmune Therapeutics Plc.
- Anchiano Therapeutics Ltd.
- Achieve Life Sciences Inc.
- Adverum Biotechnologies Inc.
- Abeona Therapeutics Inc.
- Applied Genetic Technologies Corporation
- Arbutus Biopharma Corporation
- Audentes Therapeutics
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...